Clinical and laboratory diagnosis and treatment of central precocious puberty (CPP) remain
challenging due to lack of standardization. The aim of this revision was to address the …

Introduction: Precocious puberty (PP) is one of the most common reasons for referral to
pediatric endocrinologists. Gonadotropin-releasing hormone analogs (GnRHas) are the …

Central precocious puberty (CPP) is characterized by the same biochemical and physical
features as normally timed puberty but occurs at an abnormally early age. Most cases of …

Context: GnRH agonist (GnRHa) monthly injections are frequently used in the treatment of
central precocious puberty (CPP). The 3-month leuprolide depot 11.25-and 30-mg …

Central precocious puberty (CPP) is characterized by early pubertal changes, acceleration
of growth velocity, and rapid bone maturation that often result in reduced adult height. An …

Objective Gonadotropin-releasing hormone agonist (GnRHa) treatment improves the
potential for gaining height in patients with central precocious puberty (CPP). However, most …

Introduction Gonadotropin-releasing hormone analogs (GnRHa) are the treatment of choice
for CPP. We investigated growth in GnRHa-naïve subjects, treated with leuprolide acetate 1 …

Objective Gonadotropin-releasing hormone agonists (GnRHa) are the treatment of choice
for central precocious puberty (CPP) and have been widely used for several decades. We …

Background/Aims Central precocious puberty (CPP) is due to premature activation of the
hypothalamic-pituitary-gonadal axis. It predominantly affects girls. CPP leads to lower final …

Central precocious puberty (CPP) results from early activation of the hypothalamic‐pituitary‐
gonadal (HPG) axis. The current state of knowledge of the complex neural network acting at …